EMA Refused: Ipique (bevacizumab) — Rotterdam Biologics B.V.

View source ↗

Summary

The EMA refused the marketing authorization for Ipique (bevacizumab) by Rotterdam Biologics B.V. for wet age-related macular degeneration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• Ipique (bevacizumab)

Snippet

Status: Refused. Therapeutic area: Wet Macular Degeneration. MAH: Rotterdam Biologics B.V.. Decision date: 16/12/2021